Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 8:14:1320964.
doi: 10.3389/fphys.2023.1320964. eCollection 2023.

Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism

Affiliations
Review

Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism

Xia Li et al. Front Physiol. .

Abstract

Glucose metabolism is of critical importance for cell growth and proliferation, the disorders of which have been widely implicated in cancer progression. Glucose uptake is achieved differently by normal cells and cancer cells. Even in an aerobic environment, cancer cells tend to undergo metabolism through glycolysis rather than the oxidative phosphorylation pathway. Disordered metabolic syndrome is characterized by elevated levels of metabolites that can cause changes in the tumor microenvironment, thereby promoting tumor recurrence and metastasis. The activation of glycolysis-related proteins and transcription factors is involved in the regulation of cellular glucose metabolism. Changes in glucose metabolism activity are closely related to activation of protein kinase B (PKB/AKT). This review discusses recent findings on the regulation of glucose metabolism by AKT in tumors. Furthermore, the review summarizes the potential importance of AKT in the regulation of each process throughout glucose metabolism to provide a theoretical basis for AKT as a target for cancers.

Keywords: AKT; cancer; glucose glycolysis; glucose uptake; tricarboxylic acid cycle.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
AKT can be modified through post-translational modifications (PTMs) including ubiquitination and methylation. The ubiquitination of AKT significantly regulates the activity of the mTORC1, AMPK and PTEN signaling. In addition, the CHIP, MULAN, Lysine Demethylase 4B (KDM4B) and TTC3 can ubiquitinate AKT and mediate its degradation. Furthermore, protein arginine methyltransferases 5(PRMT5) directly methylates AKT1-R391 to promote AKT activity. In addition, SETDB1-mediated methylation of AKT1 which promotes cell growth and glycolysis.
FIGURE 2
FIGURE 2
AKT regulates glucose uptake. AKT regulates the transcription of GLUTs by HIF-1α and NF-κB. Conversely AKT can directly phosphorylate targets (AS160, TBC1D1, PIKfyve, TXNIP) to regulate GLUTs trafficking.
FIGURE 3
FIGURE 3
AKT regulates glycolysis and the tricarboxylic acid cycle. AKT regulates the transcription of glycolysis enzymes by FoxOs, c-Myc, and HIF-1α. However, AKT can directly phosphorylate the glycolytic enzymes HK, PFK1, GAPDH, PGK, and PK. HK: Hexokinase; GPI: Glucose 6-phosphate isomerase; PFK1 phosphofructokinase 1; TPI triose phosphate isomerase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; PGK: phosphoglycerate kinase; PGM: Phosphoglycerate mutase; PK: Pyruvate kinase. AKT can inhibit the influx of acetyl-CoA into the TCA cycle by inhibiting PDH-E1αactivity. Furthermore, AKT can promote the conversion of glutamine into α-ketoglutarate to compensate for the depletion of the intermediates of the TCA cycle. GLS: Glutaminase, α-KG: α-ketoglutarate.

Similar articles

Cited by

References

    1. Abdel-Wahab A. F., Mahmoud W., Al-Harizy R. M. (2019). Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol. Res. 150, 104511. Epub 20191031. 10.1016/j.phrs.2019.104511 - DOI - PubMed
    1. Allen-Petersen B. L., Sears R. C. (2019). Mission possible: advances in MYC therapeutic targeting in cancer. BioDrugs. Oct. 33, 539–553. 10.1007/s40259-019-00370-5 - DOI - PMC - PubMed
    1. An D., Toyoda T., Taylor E. B., Yu H., Fujii N., Hirshman M. F., et al. (2010). TBC1D1 regulates insulin- and contraction-induced glucose transport in mouse skeletal muscle. Diabetes. Jun 59, 1358–1365. Epub 20100318. 10.2337/db09-1266 - DOI - PMC - PubMed
    1. Arnold P. K., Jackson B. T., Paras K. I., Brunner J. S., Hart M. L., Newsom O. J., et al. (2022). A non-canonical tricarboxylic acid cycle underlies cellular identity. Nat. Mar. 603, 477–481. Epub 20220309. 10.1038/s41586-022-04475-w - DOI - PMC - PubMed
    1. Bandyopadhyay G., Tang K., Webster N. J. G., van den Bogaart G., Mahata S. K. (2022). Catestatin induces glycogenesis by stimulating the phosphoinositide 3-kinase-AKT pathway. Acta Physiol. (Oxf). May 235, e13775. Epub 20220204. 10.1111/apha.13775 - DOI - PMC - PubMed